Spero Therapeutics, Inc. (SPRO) income statement
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.87−0.03 (-3.03%)
Close on Nov 18, 2026Market cap $50.90MP/E 21.8Yield –
Spero Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 12.8%
- Net margin
- 15.7%
- Return on equity, FY2025
- 16.3%
Financial strength
- Current ratio
- 6.12
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 602.4%
Valuation
- P/E ratio
- 21.8
- Price to sales
- 1.08
- Price to book
- 1.15
- Dividend yield
- –
See a number that looks wrong?